Vicarious Surgical Completes Surgical Instrument Testing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy RBOT?
Source: Newsfilter
- Successful Testing: Vicarious Surgical has completed initial integrated benchtop testing of its full suite of surgical instruments, marking a significant step toward clinical readiness for ventral hernia repair, which is expected to advance design validation and clinical preparation.
- System Performance Evaluation: The testing included the company's three core instruments: needle drivers, fenestrated graspers, and monopolar scissors, with successful system-level performance evaluations providing critical support for de-risking the path to first-in-human use, enhancing the company's competitiveness in minimally invasive surgery.
- Electrical Performance Validation: The monopolar scissors demonstrated strong motion and cutting capabilities after standard automated calibration, confirming stability under clinically relevant operating conditions and further validating the system's reliability following successful performance in prior porcine lab studies.
- Future Development Plans: Following the successful completion of benchtop testing, the company will advance to the next phase of preclinical validation, including planned cadaveric and porcine studies, continuing preparations for the first clinical use and ensuring the achievement of the design freeze milestone as scheduled.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RBOT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RBOT
About RBOT
Vicarious Surgical Inc. is a robotics company, developing technology to improve surgical procedures. The Company is combining advanced miniaturized robotics, computer science, sensing and three-dimensional (3D) visualization to build a single-port surgical robot, called the Vicarious Surgical System, that helps surgeons to perform minimally invasive surgery. The Vicarious Surgical System is capable of incision sizes of approximately 1.8 centimeters. The Vicarious Surgical System consists of a camera and instrument arms, surgeon console and patient cart. The Vicarious Surgical System has a high-performance stereoscopic camera that, when combined with robotic motion, provides full 360-degree viewing capability and is being developed to continuously map the depth of the abdominal cavity. The Vicarious Surgical System surgeon console is designed to provide all the systems necessary for the surgeon in visualizing the surgical field and controlling all the motions of the robot.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vicarious Surgical Completes Surgical Instrument Testing
- Successful Testing: Vicarious Surgical has completed initial integrated benchtop testing of its full suite of surgical instruments, marking a significant step toward clinical readiness for ventral hernia repair, which is expected to advance design validation and clinical preparation.
- System Performance Evaluation: The testing included the company's three core instruments: needle drivers, fenestrated graspers, and monopolar scissors, with successful system-level performance evaluations providing critical support for de-risking the path to first-in-human use, enhancing the company's competitiveness in minimally invasive surgery.
- Electrical Performance Validation: The monopolar scissors demonstrated strong motion and cutting capabilities after standard automated calibration, confirming stability under clinically relevant operating conditions and further validating the system's reliability following successful performance in prior porcine lab studies.
- Future Development Plans: Following the successful completion of benchtop testing, the company will advance to the next phase of preclinical validation, including planned cadaveric and porcine studies, continuing preparations for the first clinical use and ensuring the achievement of the design freeze milestone as scheduled.
See More
Vicarious Surgical Receives Approval for OTCQB Listing
- Market Transparency Boost: Vicarious Surgical's Class A common stock began trading on the OTCQB on March 24, 2026, aimed at enhancing market visibility and facilitating market maker participation, thereby increasing liquidity to support the company's strategic goal of a Nasdaq listing.
- Capital Markets Strategy Progress: CEO Stephen From stated that the OTCQB listing represents a significant step in their capital markets strategy, expected to provide better liquidity for shareholders and pave the way for a future Nasdaq listing.
- Technological Innovation Background: Founded in 2014, Vicarious Surgical focuses on developing human-like surgical robots to enhance the efficiency of minimally invasive surgeries and improve patient outcomes, backed by notable investors including Bill Gates, highlighting its technological potential and market appeal.
- Future Development Outlook: The company aims to achieve design freeze by the end of 2026, and with the OTCQB trading, Vicarious Surgical hopes to re-engage a broader investor base through ongoing operational progress, further driving business growth.
See More
Vicarious Surgical Reports Q4 Loss, Updates Cash Burn Guidance
- Earnings Miss: Vicarious Surgical reported a Q4 non-GAAP EPS of -$1.65, missing expectations by $0.28, indicating challenges in profitability that could impact investor confidence.
- Cash Position: As of December 31, 2025, the company had $9.8 million in cash and investments, which, while relatively low, supports short-term operations and reflects urgency in financial management.
- Cash Burn Rate: The cash burn rate for 2025 was $45.1 million, below the initial guidance of $50 million, indicating some progress in cost control that may lay the groundwork for future financial stability.
- Future Guidance: Vicarious Surgical updated its cash burn guidance for 2026 to approximately $19 million, demonstrating optimism regarding operational efficiency improvements and future financial health.
See More
Vicarious Surgical Completes In-Vivo Lab in December 2025, Advancing Robotic Surgery System Development
- Successful Lab Testing: Vicarious Surgical completed an in-vivo lab with porcine models in December 2025, marking a significant advancement in the development of its robotic surgery system, which is expected to facilitate a design freeze by the end of 2026.
- Key Procedure Evaluation: During the lab, surgeons independently performed critical elements of a ventral hernia repair, validating the feasibility of the pre-DV system and providing essential data for future design decisions.
- System Performance Assessment: The lab included three independent development protocols that evaluated core system capabilities such as instrument articulation, visualization, and system integration in a realistic surgical environment, ensuring minimized technical risks.
- Data-Driven Optimization: The data generated and surgeon feedback from the lab will be incorporated into ongoing design refinement and verification planning, further advancing Vicarious Surgical's innovations in minimally invasive surgery.
See More
GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
- Significant Stock Surge: GH Research PLC shares rose 18.1% to $15.64 in pre-market trading, reflecting strong market anticipation for the upcoming update on its FDA IND status and Phase 3 program for GH001, which could pave the way for future drug approvals.
- Positive Market Reaction: As the company prepares to update its treatment plan for treatment-resistant depression, investor confidence in GH Research's prospects has significantly increased, potentially attracting more investors and enhancing the company's market valuation.
- Industry-Wide Impact: The progress of GH Research may not only boost its own stock price but also positively influence the entire biopharmaceutical sector, particularly in the treatment-resistant depression space, encouraging other companies to increase their R&D investments.
- Optimistic Future Outlook: With the FDA update on the horizon, GH Research is poised to gather more clinical data in the coming months, which will provide crucial support for its subsequent marketing and commercialization strategies, strengthening its position in the competitive pharmaceutical market.
See More
Vicarious Surgical Partners with Global Engineering Firm to Enhance Development Efficiency
- Strategic Partnership Agreement: Vicarious Surgical has entered into a partnership with a global digital engineering firm to reduce operating costs and enhance development predictability and execution efficiency through a more effective mix of internal and external engineering resources.
- Software Development Outsourcing: Under the agreement, the external partner will take on significant software development responsibilities for the Vicarious Surgical robotic system, including control systems and visualization components, which is expected to accelerate development speed and lower structural costs.
- Operational Model Transformation: This collaboration allows internal teams to focus on core innovation and system integration, thereby improving the company's progress toward design freeze and clinical readiness while optimizing its cost structure.
- Ongoing Transition Plan: The external engineering partner has begun onboarding through a structured transition plan that maintains continuity across all active workstreams, supporting the company's predictable progress toward key milestones.
See More
Vicarious Surgical Completes Surgical Instrument Testing
- Successful Testing: Vicarious Surgical has completed initial integrated benchtop testing of its full suite of surgical instruments, marking a significant step toward clinical readiness for ventral hernia repair, which is expected to advance design validation and clinical preparation.
- System Performance Evaluation: The testing included the company's three core instruments: needle drivers, fenestrated graspers, and monopolar scissors, with successful system-level performance evaluations providing critical support for de-risking the path to first-in-human use, enhancing the company's competitiveness in minimally invasive surgery.
- Electrical Performance Validation: The monopolar scissors demonstrated strong motion and cutting capabilities after standard automated calibration, confirming stability under clinically relevant operating conditions and further validating the system's reliability following successful performance in prior porcine lab studies.
- Future Development Plans: Following the successful completion of benchtop testing, the company will advance to the next phase of preclinical validation, including planned cadaveric and porcine studies, continuing preparations for the first clinical use and ensuring the achievement of the design freeze milestone as scheduled.
See More
Vicarious Surgical Receives Approval for OTCQB Listing
- Market Transparency Boost: Vicarious Surgical's Class A common stock began trading on the OTCQB on March 24, 2026, aimed at enhancing market visibility and facilitating market maker participation, thereby increasing liquidity to support the company's strategic goal of a Nasdaq listing.
- Capital Markets Strategy Progress: CEO Stephen From stated that the OTCQB listing represents a significant step in their capital markets strategy, expected to provide better liquidity for shareholders and pave the way for a future Nasdaq listing.
- Technological Innovation Background: Founded in 2014, Vicarious Surgical focuses on developing human-like surgical robots to enhance the efficiency of minimally invasive surgeries and improve patient outcomes, backed by notable investors including Bill Gates, highlighting its technological potential and market appeal.
- Future Development Outlook: The company aims to achieve design freeze by the end of 2026, and with the OTCQB trading, Vicarious Surgical hopes to re-engage a broader investor base through ongoing operational progress, further driving business growth.
See More
Vicarious Surgical Reports Q4 Loss, Updates Cash Burn Guidance
- Earnings Miss: Vicarious Surgical reported a Q4 non-GAAP EPS of -$1.65, missing expectations by $0.28, indicating challenges in profitability that could impact investor confidence.
- Cash Position: As of December 31, 2025, the company had $9.8 million in cash and investments, which, while relatively low, supports short-term operations and reflects urgency in financial management.
- Cash Burn Rate: The cash burn rate for 2025 was $45.1 million, below the initial guidance of $50 million, indicating some progress in cost control that may lay the groundwork for future financial stability.
- Future Guidance: Vicarious Surgical updated its cash burn guidance for 2026 to approximately $19 million, demonstrating optimism regarding operational efficiency improvements and future financial health.
See More
Vicarious Surgical Completes In-Vivo Lab in December 2025, Advancing Robotic Surgery System Development
- Successful Lab Testing: Vicarious Surgical completed an in-vivo lab with porcine models in December 2025, marking a significant advancement in the development of its robotic surgery system, which is expected to facilitate a design freeze by the end of 2026.
- Key Procedure Evaluation: During the lab, surgeons independently performed critical elements of a ventral hernia repair, validating the feasibility of the pre-DV system and providing essential data for future design decisions.
- System Performance Assessment: The lab included three independent development protocols that evaluated core system capabilities such as instrument articulation, visualization, and system integration in a realistic surgical environment, ensuring minimized technical risks.
- Data-Driven Optimization: The data generated and surgeon feedback from the lab will be incorporated into ongoing design refinement and verification planning, further advancing Vicarious Surgical's innovations in minimally invasive surgery.
See More
GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
- Significant Stock Surge: GH Research PLC shares rose 18.1% to $15.64 in pre-market trading, reflecting strong market anticipation for the upcoming update on its FDA IND status and Phase 3 program for GH001, which could pave the way for future drug approvals.
- Positive Market Reaction: As the company prepares to update its treatment plan for treatment-resistant depression, investor confidence in GH Research's prospects has significantly increased, potentially attracting more investors and enhancing the company's market valuation.
- Industry-Wide Impact: The progress of GH Research may not only boost its own stock price but also positively influence the entire biopharmaceutical sector, particularly in the treatment-resistant depression space, encouraging other companies to increase their R&D investments.
- Optimistic Future Outlook: With the FDA update on the horizon, GH Research is poised to gather more clinical data in the coming months, which will provide crucial support for its subsequent marketing and commercialization strategies, strengthening its position in the competitive pharmaceutical market.
See More
Vicarious Surgical Partners with Global Engineering Firm to Enhance Development Efficiency
- Strategic Partnership Agreement: Vicarious Surgical has entered into a partnership with a global digital engineering firm to reduce operating costs and enhance development predictability and execution efficiency through a more effective mix of internal and external engineering resources.
- Software Development Outsourcing: Under the agreement, the external partner will take on significant software development responsibilities for the Vicarious Surgical robotic system, including control systems and visualization components, which is expected to accelerate development speed and lower structural costs.
- Operational Model Transformation: This collaboration allows internal teams to focus on core innovation and system integration, thereby improving the company's progress toward design freeze and clinical readiness while optimizing its cost structure.
- Ongoing Transition Plan: The external engineering partner has begun onboarding through a structured transition plan that maintains continuity across all active workstreams, supporting the company's predictable progress toward key milestones.
See More
